KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent TaxesDividends payablesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abbott Laboratories (ABT) Total Liabilities (2016 - 2025)

Abbott Laboratories (ABT) has disclosed Total Liabilities for 17 consecutive years, with $33.9 billion as the latest value for Q4 2025.

  • Quarterly Total Liabilities rose 0.57% to $33.9 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $33.9 billion through Dec 2025, up 0.57% year-over-year, with the annual reading at $33.9 billion for FY2025, 0.57% up from the prior year.
  • Total Liabilities hit $33.9 billion in Q4 2025 for Abbott Laboratories, up from $33.2 billion in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $88.8 billion in Q2 2024 to a low of -$21.8 billion in Q4 2022.
  • Historically, Total Liabilities has averaged $60.3 billion across 5 years, with a median of $73.1 billion in 2021.
  • Biggest five-year swings in Total Liabilities: crashed 211.81% in 2022 and later soared 465.24% in 2023.
  • Year by year, Total Liabilities stood at $19.5 billion in 2021, then plummeted by 211.81% to -$21.8 billion in 2022, then skyrocketed by 465.24% to $79.7 billion in 2023, then crashed by 57.66% to $33.8 billion in 2024, then grew by 0.57% to $33.9 billion in 2025.
  • Business Quant data shows Total Liabilities for ABT at $33.9 billion in Q4 2025, $33.2 billion in Q3 2025, and $83.7 billion in Q2 2025.